WKBH Grand Rounds: Ovarian Cancer Treatment Update
In most women with ovarian carcinoma, the disease is not diagnosed until it is at an advanced stage. Primary cytoreductive surgery is considered the standard of care for advanced ovarian carcinoma. During this conference, physicians will review indicators for acceptable use of neo-adjuvant therapy as well as when to identify acceptable use of PARP inhibitors.
Target Audience
General Surgeons, General Practitioners, Oncologists, Medical Oncologists, Hospitalists, Nurses and all other interested healthcare professionals.
Learning Objectives
- Identify indicators for an acceptable use of neo-adjuvant chemotherapy.
- Implement an acceptable use of PARP inhibitors.
Troy A. Gatcliffe, M.D.
Gynecologic Oncologist
Miami Cancer Institute
Troy A. Gatcliffe, M.D., indicated that neither he nor his spouse/partner have relevant financial relationships with commercial interest companies, and he will not include off-label or unapproved product usage in his presentation(s) or discussion(s).
Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.
Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.
Baptist Health South Florida designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 General certificate of attendance
- 1.00 Florida Board of Pharmacy